Novartis seeks U.S., European approval for breast cancer drug

07/12/2005 | Reuters

The Swiss drugmaker is seeking regulatory approval for its breast cancer drug Femara to be used immediately after surgery to help post-menopausal women fight tumors. The drug already is approved for patients who have completed a five-year post-surgery treatment with tamoxifen, but Novartis said Femara, an aromatase inhibitor, has demonstrated greater effectiveness in preventing a cancer recurrence.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT